These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related]
10. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Vaillant F; Asselin-Labat ML; Shackleton M; Forrest NC; Lindeman GJ; Visvader JE Cancer Res; 2008 Oct; 68(19):7711-7. PubMed ID: 18829523 [TBL] [Abstract][Full Text] [Related]
11. Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis. Andrechek ER; Hardy WR; Laing MA; Muller WJ Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4984-9. PubMed ID: 15051890 [TBL] [Abstract][Full Text] [Related]
12. Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Sumarsono SH; Wilson TJ; Tymms MJ; Venter DJ; Corrick CM; Kola R; Lahoud MH; Papas TS; Seth A; Kola I Nature; 1996 Feb; 379(6565):534-7. PubMed ID: 8596630 [TBL] [Abstract][Full Text] [Related]
13. Differential alteration of stem and other cell populations in ducts and lobules of TGFalpha and c-Myc transgenic mouse mammary epithelium. Chepko G; Slack R; Carbott D; Khan S; Steadman L; Dickson RB Tissue Cell; 2005 Oct; 37(5):393-412. PubMed ID: 16137731 [TBL] [Abstract][Full Text] [Related]
14. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Jacquemart IC; Springs AE; Chen WY Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488 [TBL] [Abstract][Full Text] [Related]
15. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988 [TBL] [Abstract][Full Text] [Related]
16. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Cuevas BD; Winter-Vann AM; Johnson NL; Johnson GL Oncogene; 2006 Aug; 25(36):4998-5010. PubMed ID: 16568086 [TBL] [Abstract][Full Text] [Related]
17. Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer. Wallace JA; Li F; Balakrishnan S; Cantemir-Stone CZ; Pecot T; Martin C; Kladney RD; Sharma SM; Trimboli AJ; Fernandez SA; Yu L; Rosol TJ; Stromberg PC; Lesurf R; Hallett M; Park M; Leone G; Ostrowski MC PLoS One; 2013; 8(8):e71533. PubMed ID: 23977064 [TBL] [Abstract][Full Text] [Related]
18. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070 [TBL] [Abstract][Full Text] [Related]
19. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707 [TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]